Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%

Abstract Background Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of ICI monotherapy in patients with PD‐L1 expression <50%...

Full description

Bibliographic Details
Main Authors: Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Thoracic Cancer
Subjects:
BMI
immune checkpoint inhibitor
irAE
NSCLC
PD‐L1
Online Access:https://doi.org/10.1111/1759-7714.15059

Internet

https://doi.org/10.1111/1759-7714.15059

Similar Items